Neurofibromatosis Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

  • ID: 4470337
  • Report
  • Region: Global
  • 128 pages
  • P&S Market Research
1 of 4

FEATURED COMPANIES

  • Array Biopharma Inc.
  • AstraZeneca Plc
  • Celldex Therapeutics Inc.
  • GlaxoSmithKline plc
  • Merck Co
  • Novartis AG
  • MORE
The study analyzed that the Neurofibromatosis therapeutics pipeline comprises of approximately 25 therapeutic candidates in different stages of development.

Insights on Pipeline Segments:

Majority of the pipeline drug candidates are being developed to be administered by oral route. Celldex Therapeutics Inc. and Merck Co. Inc. are in the process of developing a monoclonal antibody drug candidate, CDX0158, and Pembrolizumab respectively for the treatment of NF. Lixte Biotechnology Holdings Inc. is in the process of developing two drug candidates, in the Pre-Clinical stage of development for the treatment of neurofibromatosis (NF). In September 2016, the USFDA granted Orphan Drug Designation to BXCL101, a drug candidate of BioXcel Therapeutics Inc. for the treatment of NF type 2.

Unmet medical needs driving the neurofibromatosis therapeutics pipeline

Since there is no treatment available for NF, the growing medical needs of the people suffering from the disease are driving its therapeutics pipeline growth. High rate of recurrence/progression of the disease and poor long-term benefit of surgery can be viewed as a limitation of this treatment option.

Positive clinical trial results propelling the growth of the pipeline therapeutics of the Neurofibromatosis

The drugs being developed by the different pharmaceutical companies demonstrated positive clinical trial results which in-turn increasing their further development. For instance, In June 2014, Array BioPharma Inc. announced positive results of Phase I/II, combination of binimetinib and LEE011. Selumetinib being developed by the AstraZeneca plc. And it met primary endpoint as confirmed partial responses (tumor volume decreases from baseline of =20%) in 17 of the 24 children (71%) in Phase I study.

Some of the key players developing drugs for the treatment of neurofibromatosis include Novartis AG, AstraZeneca Plc, Pfizer Inc., GlaxoSmithKline plc, Merck & Co. Inc, BioXcel Therapeutics, Inc.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Array Biopharma Inc.
  • AstraZeneca Plc
  • Celldex Therapeutics Inc.
  • GlaxoSmithKline plc
  • Merck Co
  • Novartis AG
  • MORE
1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.3.1 Pipeline Analysis by Phase
1.3.2 Pipeline Analysis by Molecule Type
1.3.3 Pipeline Analysis by Route of Administration
1.4 Key Stakeholders

2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents
2.2.1.1 by industry participant
2.2.1.2 by company type

3. Executive Summary

4. Pipeline Outlook
4.1 Disease Overview
4.1.1 Types of Neurofibromatosis
4.2 Causes and Symptoms
4.3 Diagnosis
4.3.1 NF1 Diagnosis
4.3.2 NF2 Diagnosis
4.4 Prognosis
4.5 Prevention
4.6 Treatment
4.7 Epidemiology
4.8 Key Drivers
4.8.1 XXX
4.9 Key Barriers
4.9.1 Overlapping of NF with Many RAS-Driven Disorders
4.9.2 XXX
4.10 Neurofibromatosis Therapeutics Pipeline Analysis
4.10.1 Pipeline Analysis by Phase
4.10.2 Pipeline Analysis by Molecule Type
4.10.3 Pipeline Analysis by Route of Administration
4.10.4 Pipeline Analysis by Company

5. Neurofibromatosis (NF) Therapeutics Pipeline Analysis by Phase (2018)
5.1 Phase II
5.1.1 Selumetinib
5.1.1.1 Clinical trial
5.1.1.2 Clinical trial results
5.1.1.3 Strategic development
5.1.2 Everolimus
5.1.2.1 Clinical trial
5.1.2.2 Clinical trial results
5.1.3 Lapatinib
5.1.3.1 Clinical trial
5.1.3.2 Clinical trial results
5.1.4 XXX
5.1.4.1 Clinical trial
5.1.5 XXX
5.1.5.1 Clinical trial
5.1.6 XXX
5.1.6.1 Clinical trial
5.1.7 XXX
5.1.7.1 Clinical trial
5.1.8 XXX
5.1.8.1 Clinical trial
5.1.9 XXX
5.1.9.1 Clinical trial
5.1.9.2 Clinical trial results
5.1.10 XXX
5.1.10.1 Strategic development
5.1.11 XXX
5.1.11.1 Strategic development
5.1.12 XXX
5.1.12.1 Clinical trial
5.1.12.2 Clinical trial results
5.1.12.3 Strategic development
5.1.13 XXX
5.1.13.1 Clinical trial
5.1.14 XXX
5.1.14.1 Clinical trial
5.1.15 XXX
5.1.15.1 Clinical trial
5.2 Phase I/II
5.2.1 XXX
5.3 Phase 0
5.3.1 AR42
5.3.1.1 Clinical trials
5.3.1.2 Strategic development
5.3.2 XXX
5.3.2.1 Clinical trials
5.4 Pre-Clinical
5.4.1 LB201
5.4.1.1 Strategic development
5.4.2 LB205
5.4.3 XXX
5.4.3.1 Strategic development
5.4.4 XXX
5.4.4.1 Pre-Clinical result
5.4.4.2 Strategic development
5.5 Discovery
5.5.1 Small Molecule to Inhibit Hsp90-Alpha and TRAP1 for NF Type 2
5.5.1.1 Strategic development
5.5.2 XXX
5.5.3 XXX
5.5.3.1 Strategic development

6. Clinical Trials Review
6.1 Clinical Trials by Region
6.2 Clinical Trials by Trial Status

7. Competitive Landscape
7.1 Key Players Benchmarking for NF Therapeutics Pipeline
7.2 SWOT Analysis of Neurofibromatosis Therapeutics Pipeline
7.2.1 Strengths
7.2.2 Weaknesses
7.2.3 Opportunities
7.2.4 Threats

8. Company Profiles
8.1 Recursion Pharmaceuticals Inc.
8.1.1 Business Overview
8.1.2 Product and Service Offerings
8.2 Array BioPharma Inc.
8.2.1 Business Overview
8.2.2 Product and Service Offerings
8.3 Company 3
8.3.1 Business Overview
8.3.2 Product and Service Offerings
8.4 Company 4
8.4.1 Business Overview
8.4.2 Product and Service Offerings
8.5 Company 5
8.5.1 Business Overview
8.5.2 Product and Service Offerings
8.6 Company 6
8.6.1 Business Overview
8.6.2 Product and Service Offerings
8.7 Company 7
8.7.1 Business Overview
8.7.2 Product and Service Offerings
8.8 Company 8
8.8.1 Business overview
8.8.2 Product and Service Offerings
8.9 Company 9
8.9.1 Business Overview
8.9.2 Product and Service Offerings
8.10 Company 10
8.10.1 Business Overview
8.10.2 Product and Service Offerings

9. Appendix
9.1 Abbreviations
9.2 Related Reports

List of Tables
Comparative Features of Nf1, Nf2 And Schwannomatosis
Pipeline Analysis of Neurofibromatosis Therapeutics, by Company (2018)
Description of Selumetinib
Clinical Trials of Selumetinib
Dose-Limiting Toxic Effects of Selumetinib And Response Evaluation
Description of Everolimus
Clinical Trials of Everolimus
Description of Xxx
Clinical Trials of Xxx
Description of Xxx
Clinical Trials of Xxx
Description of Xxx
Clinical Trials of Xxx
Description of Xxx
Clinical Trials of Xxx
Description of Xxx
Clinical Trials of Xxx
Description of Xxx
Clinical Trials of Xxx
Description of Xxx
Clinical Trials of Xxx
Description of Xxx
Description of Xxx
Description of Xxx
Clinical Trials of Xxx
Phase Ii Study Design of X In Children And Adults
Description of Xxx
Clinical Trials of Xxx
Description of Xxx
Clinical Trials of Xxx
Description of Xxx
Clinical Trials of Xxx
Description of Xxx
Description of Ar42
Clinical Trials of Ar42
Description of Xxx
Clinical Trials of Xxx
Description of Lb201
Description of Lb205
Description of Xxx
Description of Xxx
Description of Small Molecule To Inhibit Hsp90-Alpha And Trap1 For Nf Type 2
Description of Drug For Xxx
Description of Xxx
Recursion Pharmaceuticals Inc. - at a Glance
Array Biopharma Inc. - at a Glance
Company 3 - at a Glance
Company 4 - at a Glance
Company 5 - at a Glance
Company 6 - at a Glance
Company 7 - at a Glance
Company 8 - at a Glance
Company 9 - at a Glance
Company 10 - at a Glance

List of Figuresresearch Methodology
Breakdown of Primary Research Respondents, by Industry Participant
Breakdown of Primary Research Respondents, by Company Type
Types of Neurofibromatosis
Clinical Diagnosis of Neurofibromatosis
Neurofibromatosis Drug Candidates In Development (2018)
Neurofibromatosis Pipeline Split, by Molecule Type (2018)
Neurofibromatosis Pipeline Split, by Route of Administration (2018)
Mean Plasma Concentration-Time And Median Pharmacokinetic Results of Selumetinib For The Three Dose Levels
Response Evaluation of Selumetinib
Inhibition of Kit Signaling by Xxx
Effects of X On Scf-Induced Kit Activation And Signaling In H526 Small Cell Lung Cancer Cells
Effects of X On Scf-Induced Kit Phosphorylation In Cho Cells Expressing Wild-Type Kit
Effects of X On Degranulation In The Mast Cell Line Lad2
Xxx Inhibits Scf-Induced Secretion of Tnf? And Gm-Csf In The Lad2 Mast Cell Line
Cross-Reactivity With Kit From Various Species
Substantial Decrease In Mast Cell
Breakdown of Clinical Trials, by Region
Breakdown of Clinical Trials, by Trial Status
Key Players Benchmarking
Swot Analysis
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Array Biopharma Inc.
  • AstraZeneca Plc
  • BioXcel Therapeutics, Inc.
  • Celldex Therapeutics Inc.
  • GlaxoSmithKline plc
  • Merck Co
  • Novartis AG
  • Pfizer Inc.
  • Recursion Pharmaceuticals Inc.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll